Lobbying Information
Subject Matters
- Consumer Issues
- Environment
- Health
- Industry
- Intellectual Property
- International Trade
- Justice and Law Enforcement
- Science and Technology
Subject Matter Details
Legislative Proposal, Bill or Resolution, Policies or Program
- Canada's Food and Consumer Safety Action Plan, specifically proposed legislation and regulation with repect to consumer products
- Canada's Food and Consumer Safety Action Plan, specifically proposed legislation and regulation with repect to therapeutic products
- Health Canada Blueprint for Renewal: Modernizing Regulatory System for Health Products and Food (formerly Bill C-51)
Policies or Program
- Federal Chemicals Management Plan as it relates to the regulation of chemicals and toxic substances, specifically Bisphenol A, Bis ( 2-ETHYLHEXYL) Phthalate, Benzyl Butyl Phthalate and Dibutyl Phthalate
- Federal Health Partnership with respect to the coordination of federal drug plan policies and programs
- Federal public drug plans, specifically the Non-Insured Health Benefits Program (Health Canada), with respect to decisions and policies that impact reimbursement of therapeutic products for plan beneficiaries
- National Pharmaceuticals Strategy, particularly with respect to Health Canada policies and programs on a common formulary
- National Pharmaceuticals Strategy, particularly with respect to Health Canada policies and programs on catastrophic drug coverage
- National Pharmaceuticals Strategy, particularly with respect to Health Canada policies and programs on expensive drugs for rare diseases
- National Pharmaceuticals Strategy, particularly with respect to Health Canada policies and programs on pricing and purchasing strategies
- Patent Act as it relates to the regulation of intellectual property for therapeutic products
- Patented Medicines Prices Review Board with respect to amendments to the guidelines for the regulation of pricing of patented drug products patentees
- Patented Medicines Prices Review Board with respect to decisions on the reporting obligations of patented drug products patentees
- Proposed and potential policies with respect to current or potential regulation of cross-border trade in pharmaceuticals, including the Export Control List
- Regulation of consumer promotion of preventatives for schedule A diseases (Project 1539)
- Science and Technology Strategy led by Industry Canada, particularly with respect to the life sciences priority under the S&T Strategy
Policies or Program, Regulation
- Canadian Environmental Protection Act as it relates to the regulation of chemicals and toxic substances, specficially Bisphenol A, Bis ( 2-ETHYLHEXYL) Phthalate, Benzyl Butyl Phthalate and Dibutyl Phthalate
- Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
- Patent Act with respect to Canada's Access to Medicines Regime (ss. 21.01-21.09)
Regulation
- Canadian Environmental Protection Act Regulations with regard to the regulation of chemicals and toxic substances, specifically Bisphenol A, Bis ( 2-ETHYLHEXYL) Phthalate, Benzyl Butyl Phthalate and Dibutyl Phthalate
- Food and Drugs Act Regulations with respect to Data Protection under C.08.004.
- Food and Drugs Act Regulations, specficially with respect to approval, regulation and life-cycle management of therapeutic products
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically proposed amendments to the Patented Medicines (Notice of Compliance) Regulations.
- Patent Act Regulations as they relate to the regulation of intellectual property for therapeutic products, specifically the Patented Medicines (Notice of Compliance) Regulations.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Environment Canada
-
Federal Environmental Assessment Review Office (FEARO)
-
Foreign Affairs, Trade and Development Canada
-
Hazardous Materials Information Review Commission (HMIRC)
-
Health Canada (HC)
-
House of Commons
-
Industry Canada
-
Justice Canada (JC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
77 Belfield Road
Toronto, ON M9W 1G6
Canada
Telephone number:
416-246-5000
Fax number:
416-240-5292
Client representative
Doug Grant, Vice President, Public Policy & Communications
Parent Company Information
Coalition Members Information
BAYER INC. is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of BAYER INC. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
BAYER INC. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
CARL BALTARE
|
Public offices held
Business address:
50 O'CONNOR ST.
SUITE 901
OTTAWA, ON K1P 6L2
Canada
Telephone number:
613-783-3438
Fax number:
613-782-2426
Consultant Firm and Address
Firm:
GLOBAL PUBLIC AFFAIRS
Address:
50 O'CONNOR ST. SUITE 901
OTTAWA, ON K1P 6L2
Canada
Telephone number:
613-783-3438
Fax number:
613-782-2426
